An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53 (Q63439685)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Behzad Foroutan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Afruj Ali Ruf

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Brenda Costall

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

27 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

151-158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

Non-Hodgkin lymphoma: diagnosis and treatment

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

p53 in signaling checkpoint arrest or apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Clinical pharmacology of 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Anthracyclines, proteasome activity and multi-drug-resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Pharmacologic circumvention of multidrug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Biochemistry of multidrug resistance mediated by the multidrug transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

DNA and its associated processes as targets for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Modern chemotherapeutic regimens in the management of aggressive non-Hodgkin lymphoma: Can they be improved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Single cell gel electrophoresis assay: a new technique for human biomonitoring studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Impact of drug transporter studies on drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

p53 Expression in normal versus transformed mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Non-Hodgkin's lymphoma: review of conventional treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Clinical relevance of P-glycoprotein expression in haematological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Molecular mechanisms of multidrug resistance in cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Assessment of genotoxic effects by lindane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

PHYTOHAEMAGGLUTININ IN RELATION TO BURKITT'S TUMOUR. (AFRICAN LYMPHOMA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Cell biological mechanisms of multidrug resistance in tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

A simple technique for quantitation of low levels of DNA damage in individual cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Preclinical and clinical aspects of biomodulation of 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Non-random cell killing in cryopreservation: implications for performance of the battery of leukocyte tests (BLT), I. Toxic and immunotoxic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.008

10.1016/J.VASCN.2006.05.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16870476%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference